Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29830966 | 1.00 | ACHE (0.39) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL123954 | 0.97 | ACHE (0.41) | ACHENFE2L2CES2CES1TAAR1 | |
| Lithium Ion SCHEMBL912832 | 0.94 | ACHE (0.39) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL1452107 | 0.94 | ACHE (0.39) | ACHENFE2L2CES2CES1TAAR1 | |
| Lithium Ion SCHEMBL29567735 | 0.94 | ACHE (0.39) | ACHENFE2L2CES2CES1TAAR1 | |
| Silver SCHEMBL1450856 | 0.94 | ACHE (0.39) | ACHENFE2L2CES2CES1TAAR1 | |
| Bromide SCHEMBL7211405 | 0.92 | ACHE (0.38) | ACHENFE2L2CES2CES1TAAR1 | |
| Bromide SCHEMBL7211403 | 0.92 | ACHE (0.38) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL20841980 | 0.81 | ACHE (0.35) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL6910972 | 0.81 | ACHE (0.31) | ACHENFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1034196-B1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | PROMERUS LLC (US) | 2005-01-12 | — | — | EP | claimed |
| US-20030023013-A1 | Catalyst and methods for polymerizing cycloolefins | THE B.F.GOODRICH COMPANY | 2003-01-30 | — | — | US | claimed |
| US-6455650-B1 | CONTACTING POLYCYCLOOLEFIN MONOMER WITH A HIGH ACTIVITY GROUP 10 TRANSITION METAL CATALYST COMPLEX TO OBTAIN POLYMER PRODUCT | THE B.F. GOODRICH COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020052454-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-05-02 | — | — | US | claimed |
| EP-1034196-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-09-13 | — | — | EP | claimed |
| WO-2000020472-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-04-13 | — | — | WO | claimed |
| US-20240279251-A1 | Monomer, Polymerizable Composition, and Polymers Derived Therefrom | 3M INNOVATIVE PROPERTIES COMPANY | 2024-08-22 | — | — | US | disclosed |
| WO-2024095078-A1 | COMPOSITIONS INCLUDING A MIXTURE OF ISOMERS OF ITACONIMIDE NORBORNENE AND CITRACONIMIDE NORBORNENE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240002586-A1 | CURABLE COMPOSITIONS, COMPOSITE FOAM, METHOD OF MAKING THE SAME, AND ARTICLE INCLUDING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2024-01-04 | — | — | US | disclosed |
| WO-2022118175-A1 | CURABLE COMPOSITIONS, COMPOSITE FOAM, METHOD OF MAKING THE SAME, AND ARTICLE INCLUDING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-06-09 | — | — | WO | disclosed |
| US-10005864-B2 | Metallocene compound, catalyst for olefin polymer, method for producing olefin polymer, and olefin polymer | JAPAN POLYETHYLENE CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170320981-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | JAPAN POLYETHYLENE CORPORATION (JP) | 2017-11-09 | — | — | US | disclosed |
| US-9783625-B2 | Metallocene compound, catalyst for olefin polymer, method for producing olefin polymer, and olefin polymer | JAPAN POLYETHYLENE CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20020052454-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6350832-B1 | CATALYTIC COSSLINKING POLYMER OF POLYCYCLOOLEFIN MONOMER, MOLDING AND SHAPING IN THE PRESENCE OF GROUP 10 TRANSITION METAL AND ANION | THE B. F. GOODRICH COMPANY | 2002-02-26 | — | — | US | disclosed |
| WO-2002010231-A2 | POLYMERIC COMPOSITIONS FOR FORMING OPTICAL WAVEGUIDES; OPTICAL WAVEGUIDES FORMED THEREFROM; AND METHODS FOR MAKING SAME | GOODRICH CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1155057-A1 | IN MOLD ADDITION POLYMERIZATION OF NORBORNENE-TYPE MONOMERS USING GROUP 10 METAL COMPLEXES | The B.F.Goodrich Co. (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1034196-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000034344-A1 | IN MOLD ADDITION POLYMERIZATION OF NORBORNENE-TYPE MONOMERS USING GROUP 10 METAL COMPLEXES | THE B.F.GOODRICH COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000020472-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | THE B.F. GOODRICH COMPANY (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279251-A1 | Monomer, Polymerizable Composition, and Polymers Derived Therefrom | PBRM1, CARM1, WASF2 | ACHE 4772/4885NFE2L2 1392/4885CES2 1821/4885 |
| US-20170320981-A1 | METALLOCENE COMPOUND, CATALYST FOR OLEFIN POLYMER, METHOD FOR PRODUCING OLEFIN POLYMER, AND OLEFIN POLYMER | CPNE4, PIN4, PIN1 | ACHE 2279/4885NFE2L2 802/4885CES2 1193/4885 |
| US-10005864-B2 | Metallocene compound, catalyst for olefin polymer, method for producing olefin polymer, and olefin polymer | CPNE4, PPOX, PIN1 | ACHE 2885/4885NFE2L2 722/4885CES2 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.